There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX – Research Report) and Tyra Bioscience (TYRA – Research Report) with bullish sentiments.
Light Up your Portfolio with Spark:
Protagonist Therapeutics (PTGX)
Wedbush analyst Yun Zhong maintained a Buy rating on Protagonist Therapeutics yesterday and set a price target of $70.00. The company’s shares closed last Thursday at $49.44.
According to TipRanks.com, Zhong has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -20.7% and a 33.2% success rate. Zhong covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protagonist Therapeutics with a $68.40 average price target, a 38.7% upside from current levels. In a report issued on March 12, J.P. Morgan also maintained a Buy rating on the stock with a $66.00 price target.
See today’s best-performing stocks on TipRanks >>
Tyra Bioscience (TYRA)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Tyra Bioscience yesterday and set a price target of $33.00. The company’s shares closed last Thursday at $9.66.
According to TipRanks.com, Biegler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.8% and a 24.5% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Acrivon Therapeutics, Inc., and Zentalis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tyra Bioscience with a $29.33 average price target.
Read More on PTGX: